N-(3-chloro-4-fluorophenyl)-7-(3-morpholin-4-ylpropoxy)quinazolin-4-amine;dihydrochloride

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: N-(3-chloro-4-fluorophenyl)-7-(3-morpholin-4-ylpropoxy)quinazolin-4-amine;dihydrochloride
• 化学式: C21H24Cl3FN4O2
• 分子量: 489.8
• InChiKey: LRRQLNDOZFISGG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.11
• 重原子数：
  31
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  59.5
• 氢给体数：
  3
• 氢受体数：
  7

文献信息

• [EN] PYRAZOLE CARBOXAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE<br/>[FR] COMPOSÉS PYRAZOLE CARBOXAMIDES, COMPOSITIONS ET PROCÉDÉS D'UTILISATION
  申请人：HOFFMANN LA ROCHE

  公开号：WO2014023258A1

  公开（公告）日：2014-02-13

  Provided herein are compounds of formula (AA): N N H HN O N N R R 6 A (R a ) p, (AA) stereoisomers or a pharmaceutically acceptable salt thereof, wherein A, R a, p, R and R 6 are defined herein, compositions including the compounds and methods of manufacturing and using the compounds for the treatment of diseases.

  本文提供了以下式（AA）的化合物：N N H HN O N N R R 6 A（R a）p，（AA）立体异构体或其药学上可接受的盐，其中A、R a、p、R和R 6在此处有定义，包括这些化合物的组合物以及用于治疗疾病的制备和使用这些化合物的方法。
• Method for preventing or treating diseases associated with the inhibition of EGFR
  申请人：ONQUALITY PHARMACEUTICALS CHINA LTD.

  公开号：US10583111B2

  公开（公告）日：2020-03-10

  The present application provides a use of a nitric oxide releasing agent in preparing a medicament, wherein the medicament is used for preventing or treating EGFR inhibition associated epithelial diseases in a subject. The present application further provides a pharmaceutical composition or a kit comprising EGFR inhibitor and nitric oxide releasing agent.

  本申请提供了一氧化氮释放剂在制备药物中的用途，其中所述药物用于预防或治疗受试者中与表皮生长因子受体抑制相关的上皮疾病。本申请进一步提供了一种药物组合物或试剂盒，其包含表皮生长因子受体抑制剂和一氧化氮释放剂。
• PYRAZOLE CARBOXAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE
  申请人：F.Hoffmann-La Roche AG

  公开号：EP2882718A1

  公开（公告）日：2015-06-17
• METHOD FOR PREVENTING OR TREATING DISEASES ASSOCIATED WITH THE INHIBITION OF EGFR
  申请人：Shanghai Xiaowu Pharma Tech CO., LTD.

  公开号：US20190282536A1

  公开（公告）日：2019-09-19

  The present application provides a use of a nitric oxide releasing agent in preparing a medicament, wherein the medicament is used for preventing or treating EGFR inhibition associated epithelial diseases in a subject. The present application further provides a pharmaceutical composition or a kit comprising EGFR inhibitor and nitric oxide releasing agent.